CD19 and lymphoma: In vitro and in vivo experiments showed remarkable efficacy as a single agent in CD19+ lymphoma and leukemia models [113, 120] and an increased potency of the PBD dimer compared to ADCs delivering tubulin inhibitor drugs [113].